

DISCLOSURE OF RELEVANT RELATIONSHIPS & CONFIDENTIALITY STATEMENTS

For NIA-AA Guidelines Workgroup

Confidential

DISCLOSURE OF RELEVANT RELATIONSHIPS

For each of the categories below, (1) please disclose relationships that cover the last 12 months and for anticipated activities in the coming 12 months as of approximately April 2017. If you have none, please write “none.” Relationships apply to you and to spouse or dependent children. (2) For each relationship, please indicate whether it is a “**Significant (≥\$1,000) Financial Interest**” Financial interests include but are not limited to salary, consulting and / or speaker fees, honoraria, research support, equity interests (e.g., stocks, stock options, or other ownership interests), and intellectual property rights (e.g., patents, copyrights and royalties from such rights).

All of the following are “**Significant (≥\$1,000) Financial Interest**”

1. Research funding (federal, foundation and corporate) relevant to the topic of Alzheimer’s disease.

Federal

Australian Government

1. NHMRC APP1085606: An amyloid imaging study using the twin design.
2. NHMRC APP10475151: Imaging Neurodegenerative Disease. Practitioner Fellowship.
3. NHMRC APP1140853: Molecular Imaging to Advance Treatment of Dementia. Practitioner Fellowship commencing 2018.
4. NHMRC APP1127007: Traumatic Brain Injury, Post Traumatic Stress Disorder and the Risk of Neurodegenerative Disease: a study of tau and beta-amyloid accumulation, brain structure and function several decades after injury.
5. NHMRC1132604 Program Grant: Biomarkers to aid clinical trials for neurodegenerative disease.
6. CRC for Mental Health: Imaging AD and Psychosis.

US Government

1. Department of Defense: Tau imaging in TBI and PTSD in Vietnam Veterans

Corporate

1. Avid/Lilly: Florbetapir Centiloid Project
2. Avid/Lilly: Tau imaging with AV1451
3. GE Healthcare: Tau imaging with GE126
4. Piramal Imaging: Evaluating PI2620 tau tracer
5. Enigma: Evaluating MK6240 tau tracer
6. Astra Zeneca: Prescreening for prodromal AD trials.
7. Biogen: Prescreening for prodromal AD trials

2. Consulting to a for-profit company (paid and unpaid) relevant to the topic of Alzheimer’s disease.

1. Avid/Lilly: Data Management Board for Phase III study of AV1451
2. Speaker: Biogen sponsored symposium
3. Speaker GE sponsored Symposium.

3. Ownership of property relevant to the topic of Alzheimer's disease (patents filed or approved, licenses and other property shares) -- for each, please indicate whether you do or do not accept royalties.

Named Inventor on Provisional Patent: 14/365,745 (USA). Method and apparatus for assessment of medical images. Not commercialized at this time.

4. Equity in companies whose work is relevant to the topic of Alzheimer's disease

Nil

5. Employment in companies whose work is relevant to the topic of Alzheimer's disease

Nil

6. Relevant scientific work to the NIA-AA Workgroup discussions.

Imaging leader of a large Australian longitudinal study of aging and AD – AIBL.
Leader in the evaluation of amyloid and tau tracers.

I will immediately notify NIA-AA Workgroup leads if a change occurs in any of the above during the tenure of my responsibilities,

Christopher C. Rowe _____
Name

C. Rowe
Signature

_____ _15th August 2017_
Date